EP0914101A2 - Systemes therapeutiques transdermiques - Google Patents

Systemes therapeutiques transdermiques

Info

Publication number
EP0914101A2
EP0914101A2 EP97931732A EP97931732A EP0914101A2 EP 0914101 A2 EP0914101 A2 EP 0914101A2 EP 97931732 A EP97931732 A EP 97931732A EP 97931732 A EP97931732 A EP 97931732A EP 0914101 A2 EP0914101 A2 EP 0914101A2
Authority
EP
European Patent Office
Prior art keywords
general formula
matrix
group
transdermal therapeutic
copolymer
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP97931732A
Other languages
German (de)
English (en)
Inventor
Ralph Lipp
Clemens Günther
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of EP0914101A2 publication Critical patent/EP0914101A2/fr
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/569—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone substituted in position 17 alpha, e.g. ethisterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates

Definitions

  • the invention relates to transdermal therapeutic systems for the controlled release of gestagens of the second and third generation, which are at least partially dissolved in a matrix and optionally of estrogens, which are characterized in that their matrix is a copolymer of one or more vinyl group-containing esters or amides of the general formula I
  • X symbolizes a -COO group, a -CONH group or a -OCO group
  • R ⁇ represents a hydrogen atom or an alkyl group with a maximum of 4 carbon atoms
  • R2 represents a hydrogen atom or an alkyl group with a maximum of 12 carbon atoms, and an N-vinyl lactam of the general formula ⁇
  • n is a number from 3 to 5
  • the steroidal active ingredients dissolved in the matrix essentially not crystallizing out over a longer period of time.
  • the invention relates to such transdermal therapeutic systems whose matrix is a copolymer which contains 0.5 to 2.5 mol and preferably 0.75 to 1.5 mol of one or more vinyl group-containing esters per mol of N-vinyl lactone of the general formula II or contains amides of the general formula I.
  • Transdermal therapeutic systems are known to be multi-layer plasters that are fixed on the skin and continuously release the active ingredient percutaneously over a longer period of time.
  • Transdermal therapeutic systems essentially consist of a cover film which is impermeable to water, penetration enhancers and active ingredients, a matrix which comprises the skin pressure sensitive adhesive, penetration enhancer and medicament and a removable protective film.
  • JP-A 02,196,714 - (ref. CA. 113,1990) and JP-A 04,342,532 transdermal therapeutic systems have been described which use norethisterone as progestogen of the so-called first generation or estradiol as active ingredients in a matrix of a copolymer of acrylic acid-2 -ethylhexyl ester and N-vinyl pyrrolidone included.
  • the object of the present invention was to provide transdermal therapeutic systems, the gestagens of the so-called second and third generations optionally in combination with estrogen, which are characterized in that the steroidal active ingredients do not crystallize substantially.
  • Gestagens of the so-called second and third generation are, for example, the levonorgestrel, the gestodene, the desogestrel, the 3-keto-desogestrel, the norgestimate, the dienogest, the dihydrospirenone and the cyproterone and its acetate.
  • Suitable estrogens according to the present invention are both natural estrogens such as, for example, estradiol and its esters, such as, for example, estradiol esters, and synthetic estrogens such as ethinyl estradiol and in particular the 14 ⁇ , 17 ⁇ -ethanoestra-1,3,5 (10) -triene- 3,17ß-diol (WO-88/01275) and the 14 ⁇ , 17 ⁇ -ethanoestra-l, 3,5 (10) -triene-3,16 ⁇ , 17ß-triol (WO-91/08219).
  • natural estrogens such as, for example, estradiol and its esters, such as, for example, estradiol esters
  • synthetic estrogens such as ethinyl estradiol and in particular the 14 ⁇ , 17 ⁇ -ethanoestra-1,3,5 (10) -triene- 3,17ß-diol (WO-88/01275) and the 14 ⁇ , 17 ⁇ -ethanoestra-l, 3,5 (
  • copolymers required as a matrix can be purchased, such as the copolymers contained in the "TSR Adhesive Solution" from the Japanese company Sekisui.
  • the transdermal systems according to the invention can optionally additionally 1 to 35%, preferably 5 to 20%, of a water-soluble polymer of vinylpyrrolidone, such as, for example, polyvinylpyrrolidone (for example Kollidn 12PF, KoUidon 17PF, Kollidon 25, Kollidon 30 from BASF, Ludwigshafen, Germany or a water-soluble copolymer of vinylpyrrolidone and vinyl acetate (eg Kollidon VA 64, BASF).
  • a water-soluble polymer of vinylpyrrolidone such as, for example, polyvinylpyrrolidone (for example Kollidn 12PF, KoUidon 17PF, Kollidon 25, Kollidon 30 from BASF, Ludwigshafen, Germany or a water-soluble copolymer of vinylpyrrolidone and vinyl acetate (eg Kollidon VA 64, BASF).
  • they can also be prepared in a manner known per se by, for example, a solution or emulsion of the vinyl group-containing esters or amides of the general formula I and the N-vinyl lactams of the general formula II in the presence of radical formers such as peroxides (such as benzoyl peroxide or lauryl peroxide ), and optionally crosslinking agents, control substances and telogens (such as hexamethyl diisocyanate, diphenylmethane diisocyanate, hexamethylene glycol and trimethylpropanol triacrylate) polymerized (Houben-Weyl: "Methods of Organic Chemistry", Georg Thieme Verlag, DE-Stuttgart, 4th edition, volume XTV71, p 100 ff).
  • radical formers such as peroxides (such as benzoyl peroxide or lauryl peroxide ), and optionally crosslinking agents, control substances and telogens (such as hex
  • Suitable vinyl group-containing esters and amides of the general formula I are, for example: a) vinyl esters, such as vinyl acetate, vinyl propionate, vinyl pivalate or vinyl 2-ethylhexanoate (Ul nann's Encyclopedia of Industrial Chemistry, 5th edition, Vol A 22, 1993, 1 ff), b) methacrylic acid esters, such as methyl methacrylate, the methacrylic acid tert-butyl ester, the methacrylic acid allyl ester and the methacrylic acid 2-ethylheyl ester (UUmann's Encyclopedia of Industrial Chemistry, 5th edition, Vol A 21, 1992, 473 ff) and in particular c) acrylic acid and its esters and amides, such as the acrylic acid amide , the acrylic acid methyl ester, the acrylic acid ethyl ester, the acrylic acid 2-hydroxyethyl ester, the acrylic acid allyl ester and the acrylic acid 2-ethylhexyl ester
  • Suitable vinyl lactams of the general formula II are N-vinylpiperidone, N-vinylcaprolactam and in particular N-vinylpyrrolidone (UUmann's Encyclopedia of Industrial Chemistry, 5th edition, Vol A 21, 752 ff).
  • transdermal therapeutic systems can also be carried out under the conditions which are well known to the person skilled in the art (Yie W. Chien: “Transdermal Controlled Systemic Medications", Marcel Dekker Inc., New York and Basel, 1987, Dr. Richard Baker: "Analysis of Transdermal Drug Delivery Patents 1934 to 1984” and "Analysis of Recent Transdermal Delivery Patents, 1984 - 1986 and Enhancers”; see also, for example, WO 90/04398, WO 93/08795 and WO 95/22322).
  • transdermal therapeutic system which consists of
  • an impermeable cover layer one to three matrix layer (s) adhering to the cover layer and, if desired, penetration-enhancing agents and other auxiliaries, comprising a self-adhesive or a copolymer of a skin adhesive covered or surrounded by a penetration-enhancing agent, if desired, or surrounded several esters or amides of the general formula I containing vinyl groups
  • X symbolizes a -COO group, a -CONH group or a -OCO group
  • Rj represents a hydrogen atom or an alkyl group with a maximum of 4 carbon atoms
  • R 2 represents a hydrogen atom or an alkyl group with a maximum of 12 carbon atoms
  • CH CH 2 where n is a number from 3 to 5 and a removable protective layer,
  • a cover provided with a pressure-sensitive adhesive containing a penetration-enhancing agent if desired, one or two matrix layer (s) consisting of a pressure-sensitive adhesive border that is uncovered and attached to the pressure-sensitive adhesive by means of a cover, and optionally penetration-enhancing agents and other additives a copolymer of an ester and amide of the general formula I containing vinyl groups
  • X symbolizes a -COO group, a -CONH group or a -OCO group
  • Rl represents a hydrogen atom or an alkyl group with a maximum of 4 carbon atoms
  • R 2 represents a hydrogen atom or an alkyl group with a maximum of 12 carbon atoms
  • wo ⁇ n n is a number from 3 to 5, and there is a removable protective layer.
  • a transdermal therapeutic system represents a simple matrix system. It can, for example, be round, oval or rectangular in shape and can be produced, for example, as follows:
  • a solution of up to 25 percent by weight of active ingredient or mixture of active ingredients and penetration-enhancing agents, 30 to 70 percent by weight of the copolymer, filled up to 100 percent by weight with a suitable volatile solvent is spread on a flat, impervious cover layer. After drying, a second and, if desired, even a third layer, optionally containing active ingredient, penetration-enhancing agents and adhesive, can be applied to this layer and dried. Then the matrix system is provided with a removable protective layer.
  • the system can be additionally covered or surrounded with a skin pressure-sensitive adhesive before the removable protective layer is applied.
  • Suitable volatile solvents are, for example, lower alcohols, ketones or esters of lower carboxylic acids such as ethanol, isopropanol, acetone or ethyl acetate, polar ethers such as tetrahydrofuran, lower hydrocarbons such as cyclohexane, benzene or toluene or else lower halogenated hydrocarbons such as dichloromethane or tetrachloroethane. There is no need to explain that mixtures of these solvents are also suitable.
  • Suitable penetration-enhancing agents are, for example, monohydric or polyhydric alcohols, such as ethanol, 1,2-propanol, or benzyl alcohol, fatty alcohols or fatty acids with 8 to 18 carbon atoms, such as lauryl alcohol, cetyl alcohol, stearic acid or oleic acid, or fatty acid esters and dicarboxylic acid diesters with up to to 24 carbon atoms.
  • monohydric or polyhydric alcohols such as ethanol, 1,2-propanol, or benzyl alcohol
  • fatty alcohols or fatty acids with 8 to 18 carbon atoms such as lauryl alcohol, cetyl alcohol, stearic acid or oleic acid, or fatty acid esters and dicarboxylic acid diesters with up to to 24 carbon atoms.
  • Fatty acid esters which are suitable as penetration enhancers are, for example, those of acetic acid, caproic acid, lauric acid, myristic acid and palmitic acid, such as, for example, the methyl esters, ethyl esters, isopropyl esters, tert-butyl esters or monoglyceric acid esters.
  • Particularly preferred esters are those of myristic acid or oleic acid, such as their methyl ester or in particular their isopropyl ester.
  • Suitable dicarboxylic acid esters are, for example, the diisopropyl adipate, the diisobutyl adipate and the diisopropyl sebacate.
  • Further penetration-enhancing agents are phosphatide derivatives such as lecithin, terpenes, amides, ketones, urea and its derivatives or ethers such as dimethyl isosorbide. Mixtures of these penetration-enhancing agents are of course also suitable.
  • All films that are commonly used in transdermal therapeutic systems are suitable as a protective layer. Such films are siliconized or fluoropolymer coated, for example.
  • 10 to 100 ⁇ m thick films of polyethylene or polyester can be used as a top layer, optionally pigmented or metallized.
  • the drug layer applied thereon preferably has a thickness of 20 to 500 ⁇ m.
  • the active ingredients are preferably dispensed over an area of 5 to 100 cm.
  • the gestagen and possibly penetration enhancers can be introduced into the matrix applied to the impermeable cover layer, while the layer or layers below contains the estrogens and optionally also penetration enhancers.
  • the layer or layers below contains the estrogens and optionally also penetration enhancers.
  • a transdermal therapeutic system according to variant b) can, for example, also be round, oval or rectangular and can be produced as follows:
  • a cover is coated with a skin pressure sensitive adhesive. Then you glue one to three areas with a cover, produced according to variant a), which contain the active ingredient (s) and, if appropriate, penetration-enhancing agents, so that the cover has a sufficient edge for attachment to the skin and, in the case of several areas, also sufficient gaps and provides it with a removable protective layer.
  • the materials used in these matrix systems can be the same as those used in variant a).
  • transdermal therapeutic systems according to the invention are distinguished from those known from the prior art in that, even in the case of a very high concentration of second and third generation gestagens, in combination with an estrogen in the matrix they essentially do not exist over a longer period of time Active ingredient crystals are formed.
  • transdermal therapeutic systems containing 5% gestodene, 2% levonorgestrel, mixtures of 2% levonorgestrel and 2% estradiol or 4% gestodene and 4% estradiol are contained in a skin adhesive from Sekisui (consisting of a copolymer of 35% vinylpyrrolidone and 65% of 2-ethylhexyl acrylate), even after 10 months of storage at 25 ° C in the microscopic image, free of crystals, while the corresponding systems in a polymer of pure 2-ethylhexyl acrylate are contained in crystals after only three months of storage at 25 ° C.
  • Sekisui consisting of a copolymer of 35% vinylpyrrolidone and 65% of 2-ethylhexyl acrylate
  • Essentially crystal-free according to the present invention is understood to mean that the transdermal therapeutic systems according to the invention are crystal-free in the microscopic image with a 2% gestagen loading over a storage period of 25 months at 25 ° C.
  • the concentration of the active ingredient or the active ingredients in the transdermal therapeutic systems according to the invention is of course dependent on the type of active ingredient used and is usually 0.1 to 25 percent by weight for gestagens and estrogens, with 0.5 to 5 percent by weight being preferred. A concentration of 0.5 to 2.5% levonorgestrel and 1 to 5% estradiol is particularly preferred.
  • levonorgestrel 0.5 g of levonorgestrel are suspended in 5 g of isopropanol and, after stirring for 30 minutes, 68.1 g of a 36% solution of a copolymer of vinylpyrrolidone and 2-
  • Ethylhexyl acrylate in ethyl acetate (TRS-Adhesive Solution from Sekisui, Osaka, Japan). It is made up to 95 g with isopropanol and stirred until everything is
  • a cover film backing, e.g. Saran-Hytel-Colaminat from the company
  • a transdermal therapeutic system is produced under the conditions of Example 1, but with the additional use of 1.0 g of estradiol, the proportion of TSR adhesive solution being reduced accordingly to 66.7 g.
  • a transdermal therapeutic system is produced at 63.9 g TSR Adhesive Sulution.
  • Example 2 Under the conditions of Example 1, but using 2.0 g gestodene, 2.0 g estradiol, 5.0 g lauryl alcohol and 58.3 g TSR adhesive solution, a transdermal therapeutic system is established.
  • Hexamethylene glycol di-methacrylic acid esters are mixed with 23.4 g of ethyl acetate.
  • the polymer solution thus obtained in ethyl acetate can be used in the same manner as the commercially available TRS-Adhesive Solution in Examples 1 to 4 for the production of transdermal therapeutic systems.
  • a cover film backing, e.g. Saran-Hytel-Colaminat from the company
  • the extent and rate of percutaneous absorption by the agents according to the invention can be determined by means of in vitro testing.
  • Freshly prepared and subcutaneous fat-free skin of the hairless mouse is clamped in a Franz diffusion cell which contains 50% polyethylene glycol (MW 400) solution as the acceptor medium. After application of a matrix TTS, the concentration time course of the steroid in the acceptor medium is determined using suitable analysis.
  • the matrix TTS containing levonorgestrel and estradiol listed in Table 1 were tested in this model.

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

L'invention concerne des systèmes thérapeutiques transdermiques pour l'administration contrôlée de gestagènes de deuxième et de troisième générations, et le cas échéant d'oestrogènes, au moins partiellement dissous dans une matrice. Ces systèmes se caractérisent en ce que leur matrice comporte un copolymère d'un ou plusieurs esters ou amides qui contiennent des groupes vinyle et répondent à la formule générale (I), dans laquelle X symbolise un groupe -COO-, un groupe -CONH- ou un groupe -OCO-, R1 désigne un atome d'hydrogène ou un groupe alkyle avec au maximum 4 atomes de carbone, et R2 désigne un atome d'hydrogène ou un groupe alkyle avec au maximum 12 atomes de carbone, et un N-vinyllactame qui répond à la formule générale (II), dans laquelle n est un chiffre compris entre 3 et 5.
EP97931732A 1996-07-11 1997-07-11 Systemes therapeutiques transdermiques Withdrawn EP0914101A2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE19629468 1996-07-11
DE19629468A DE19629468A1 (de) 1996-07-11 1996-07-11 Transdermale therapeutische Systeme
PCT/DE1997/001517 WO1998002147A2 (fr) 1996-07-11 1997-07-11 Systemes therapeutiques transdermiques

Publications (1)

Publication Number Publication Date
EP0914101A2 true EP0914101A2 (fr) 1999-05-12

Family

ID=7800460

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97931732A Withdrawn EP0914101A2 (fr) 1996-07-11 1997-07-11 Systemes therapeutiques transdermiques

Country Status (5)

Country Link
US (1) US20010009673A1 (fr)
EP (1) EP0914101A2 (fr)
AU (1) AU3539297A (fr)
DE (1) DE19629468A1 (fr)
WO (1) WO1998002147A2 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5783208A (en) * 1996-07-19 1998-07-21 Theratech, Inc. Transdermal drug delivery matrix for coadministering estradiol and another steroid
DE19906152B4 (de) * 1999-02-10 2005-02-10 Jenapharm Gmbh & Co. Kg Wirkstoffhaltige Laminate für Transdermalsysteme
DE10019171A1 (de) * 2000-04-07 2001-10-18 Schering Ag Zusammensetzungen zur Verwendung als Penetrationsverstärker in transdermalen Formulierungen für hoch lipophile Wirkstoffe
DE10211832A1 (de) * 2002-03-16 2003-10-02 Lohmann Therapie Syst Lts Hormonhaltiges transdermales therapeutisches System mit einem Wirkstoffreservoir auf der Basis von Vinylacetat-Vinylpyrrolidon-Copolymer mit verbesserter Kohäsion
US20050202073A1 (en) * 2004-03-09 2005-09-15 Mylan Technologies, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
US9205062B2 (en) 2004-03-09 2015-12-08 Mylan Pharmaceuticals, Inc. Transdermal systems containing multilayer adhesive matrices to modify drug delivery
BRPI0913214B1 (pt) * 2008-05-30 2022-05-17 Mylan Laboratories Inc Dispositivo de fornecimento de drogas transdérmico e método de fabricação do mesmo
DE102010040299A1 (de) 2010-09-06 2012-03-08 Bayer Schering Pharma Aktiengesellschaft Transdermale therapeutische Systeme mit kristallisationsinhibierender Schutzfolie (Release Liner)
WO2012092165A1 (fr) * 2010-12-29 2012-07-05 Noven Pharmaceuticals, Inc. Dispositif d'administration transdermique de lévonorgestrel et administration
CA2856520C (fr) 2011-11-23 2021-04-06 Therapeuticsmd, Inc. Preparations et therapies de substitution pour hormonotherapie naturelle combinee
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
AR100562A1 (es) 2014-05-22 2016-10-12 Therapeuticsmd Inc Composición farmacéutica de estradiol y progesterona para terapia de reemplazo hormonal
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
US10286077B2 (en) 2016-04-01 2019-05-14 Therapeuticsmd, Inc. Steroid hormone compositions in medium chain oils
AU2017239645A1 (en) 2016-04-01 2018-10-18 Therapeuticsmd, Inc. Steroid hormone pharmaceutical composition
US11633405B2 (en) 2020-02-07 2023-04-25 Therapeuticsmd, Inc. Steroid hormone pharmaceutical formulations

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4693887A (en) * 1983-09-15 1987-09-15 The Kendall Company Microphase separated hydrogels for controlled release of bioactive materials
AU622162B2 (en) * 1988-04-22 1992-04-02 Ciba-Geigy Ag Transdermal monolith systems
US5200190A (en) * 1988-10-11 1993-04-06 Sekisui Kagaku Kogyo Kabushiki Kaisha Percutaneous pharmaceutical preparation
JPH02196714A (ja) * 1989-01-26 1990-08-03 Sekisui Chem Co Ltd 経皮吸収貼付剤
EP0409383B1 (fr) * 1989-07-21 1994-04-06 Izhak Blank Compositions à base d'estradiol et procédés d'application topique
DE4210711A1 (de) * 1991-10-31 1993-05-06 Schering Ag Berlin Und Bergkamen, 1000 Berlin, De Transdermale therapeutische systeme mit kristallisationsinhibitoren
DE4227989A1 (de) * 1992-08-21 1994-06-09 Schering Ag Mittel zur transdermalen Applikation enthaltend 3-Keto-desogestrel
DE4329242A1 (de) * 1993-08-26 1995-03-02 Schering Ag Mittel zur transdermalen Applikation enthaltend Gestodenester
AU692504B2 (en) * 1993-12-27 1998-06-11 Akzo Nobel N.V. Percutaneously absorbable preparation
DE4405899A1 (de) * 1994-02-18 1995-08-24 Schering Ag Mittel zur transdermalen Applikation enthaltend Desogestrel
AU3723695A (en) * 1994-09-14 1996-03-29 Minnesota Mining And Manufacturing Company Transdermal device for delivery of levonorgestrel
CA2198390C (fr) * 1994-09-14 2009-08-11 James E. Garbe Matrice pour l'administration transdermique de medicaments

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO9802147A3 *

Also Published As

Publication number Publication date
US20010009673A1 (en) 2001-07-26
DE19629468A1 (de) 1998-01-15
WO1998002147A3 (fr) 1998-03-12
WO1998002147A2 (fr) 1998-01-22
AU3539297A (en) 1998-02-09

Similar Documents

Publication Publication Date Title
EP0914101A2 (fr) Systemes therapeutiques transdermiques
EP0695177B1 (fr) Pansement a substance active
EP0655916B1 (fr) Agent d'application transdermique contenant du 3-ceto-desogestrel
EP0840621B1 (fr) Emplatre liberant des hormones
DE69434537T2 (de) System für transdermale verabreichung mit niedrigem fluss für hochwirksame medikamente
EP0744944B1 (fr) Systemes therapeutiques transdermiques contenant des steroides sexuels
DE69829961T2 (de) Transdermale vorrichtung zur verabreichungvon von testosteron
DE69205010T2 (de) Transdermales estradiol als therapeutisches system.
WO1990004397A1 (fr) Preparation pour application transcutanee renfermant du gestodene
EP0715518A1 (fr) Agent contenant des esters de gestodene pour application transdermique
EP1347749A2 (fr) Systeme therapeutique transdermique contenant l'agent actif oxybutynine
DE3587048T2 (de) Pharmazeutische praeparate.
EP1485072B1 (fr) Systeme therapeutique transdermique contenant des hormones, comportant un reservoir d'agents actifs a base de copolymere de vinylacetate-vinylpyrrolidone presentant une meilleure cohesion
EP1103260A2 (fr) Système transdermique pour l'administration de clonidine
DE3729299A1 (de) Transdermales therapeutisches system
DE69216963T2 (de) Acrylgel und dieses enthaltende Zusammensetzung zur perkutanen Absorption
DE3911699C2 (de) Pharmazeutische Zubereitung mit einem perkutan absorbierbaren Arzneimittel
DE10118282A1 (de) Haftkleber auf Basis von Ethylen-Vinylacetat-Copolymeren und Klebharzen, für medizinische Verwendungszwecke
WO1994002151A1 (fr) SYSTEME THERAPEUTIQUE TRANSCUTANE LIBERANT DE L'ESTRADIOL 17-β(ANHYDRE)
DE69813982T2 (de) Stabilisierte Zusammensetzungen zur perkutan Absorption
EP0380989B1 (fr) Pansement pour l'administration transdermique
EP0744943A1 (fr) Agent d'application transdermique contenant du desogestrel
EP0848620A1 (fr) Agent pour application transdermique contenant des esters de 3-ketodesogestrel
DE4339400A1 (de) Wirkstoffpflaster
DE60108870T2 (de) Transdermales Verabreichungssystem für die Behandlung von Harnwegserkrankungen

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19990127

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20010725